Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.57 USD | -0.15% |
|
+6.08% | +9.70% |
09/07 | RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating | MT |
01/07 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 830.77Cr | |
+7.40% | 10TCr | |
+8.42% | 4.22TCr | |
-13.04% | 3.23TCr | |
+80.80% | 2.98TCr | |
-10.92% | 1.61TCr | |
+1.93% | 1.44TCr | |
-6.77% | 1.2TCr | |
+177.16% | 1.07TCr | |
+4.12% | 889.02Cr |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating